Neumora Therapeutics, Inc. Cash Flow Conversion Efficiency
Neumora Therapeutics, Inc. cash flow conversion efficiency. Based on the latest financial reports, Neumora Therapeutics, Inc. (NMRA) has a cash flow conversion efficiency ratio of -0.353x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-46.63 Million) by net assets ($132.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Neumora Therapeutics, Inc. (2019–2024)
Cash flow conversion efficiency of Neumora Therapeutics, Inc. from 2019 to 2024. This chart illustrates how Neumora Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Neumora Therapeutics, Inc. stock price for real-time trading data and today's change.
Neumora Therapeutics, Inc. Cash Flow Conversion Ratio Explained
Neumora Therapeutics, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Neumora Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neumora Therapeutics, Inc. ranked by their cash flow conversion efficiency. Also see market value of Neumora Therapeutics, Inc. for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Centrica PLC
LSE:CNA
|
0.012x |
|
Rich Honour International Designs Co Ltd
TW:6754
|
0.114x |
|
Chuwa Wool Industry Co Taiwan Ltd
TW:1439
|
0.032x |
|
TDM Berhad
KLSE:2054
|
0.043x |
|
Trivago NV
NASDAQ:TRVG
|
0.091x |
|
Bank Panin Syariah Tbk
JK:PNBS
|
0.030x |
|
Weir Group PLC
LSE:WEIR
|
0.020x |
|
Mobiletron Electronics Co Ltd
TW:1533
|
0.018x |
Annual Cash Flow Conversion Efficiency for Neumora Therapeutics, Inc. (2019–2024)
The table below shows the annual cash flow conversion efficiency of Neumora Therapeutics, Inc. from 2019 to 2024. Review Neumora Therapeutics, Inc. leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $287.06 Million | $-182.94 Million | -0.637x | -83.08% |
| 2023-12-31 | $469.08 Million | $-163.28 Million | -0.348x | -235.38% |
| 2022-12-31 | $-446.85 Million | $-114.90 Million | 0.257x | +10.88% |
| 2021-12-31 | $-325.22 Million | $-75.42 Million | 0.232x | -18.21% |
| 2020-12-31 | $-94.38 Million | $-26.76 Million | 0.284x | -99.98% |
| 2019-12-31 | $-21.00K | $-26.76 Million | 1274.286x | -- |
About Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive diso… Read more